Arthneeti

Aarey Drugs & Pharmaceuticals Share Price & Earnings Call Analysis

₹105.76-2.93% today
Market cap
₹337 Cr
P/E
80.84
ROE
2.75%
PEG
46.46
Price to sales
0.82
Debt to equity
0.33
52W high / low
₹114 / ₹50.8
Sales growth (5Y)
6.27%
EBITDA margin
1.64%
Net profit margin
0.84%
Promoter holding
41.46%
Sales (last year)
₹415 Cr

Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Aarey Drugs rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Aarey Drugs.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Aarey Drugs

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Aarey Drugs

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +62.47162.8850.9657.8376.48210.35126.91105.14133.79108.10102.2184.1696.43
Expenses +60.94160.3649.6255.9973.78211.79125.73101.42131.59112.31100.5081.5297.94
Operating Profit1.532.521.341.842.70-1.441.183.722.20-4.211.712.64-1.51
OPM %2.45%1.55%2.63%3.18%3.53%-0.68%0.93%3.54%1.64%-3.89%1.67%3.14%-1.57%
Other Income +0.480.840.700.840.295.141.580.020.687.541.550.794.18
Interest0.710.200.420.410.470.400.960.490.581.301.041.260.92
Depreciation0.551.020.891.271.061.150.471.510.900.410.490.690.83
Profit before tax0.752.140.731.001.462.151.331.741.401.621.731.480.92
Tax %-33.33%83.18%0.00%-22.00%30.14%-0.47%6.77%8.62%48.57%71.60%20.81%31.08%38.04%
Net Profit +1.000.360.721.231.022.151.241.600.720.471.371.020.57
EPS in Rs0.390.140.280.480.400.770.440.570.250.170.480.360.20

Financials of Aarey Drugs

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +200213246396349354298348493419396474391
Expenses +198212245386342347294344481411391471392
Operating Profit11110883511843-1
OPM %1%1%0%2%2%2%1%1%2%2%1%1%-0%
Other Income +233334773371014
Interest1124222223455
Depreciation1111111122222
Profit before tax11288978106566
Tax %22%23%29%31%25%27%20%21%35%37%12%34%
Net Profit +1115676774543
EPS in Rs0.620.650.773.022.642.802.482.782.581.491.671.421.21
Dividend Payout %0%0%0%0%0%4%0%0%0%0%0%0%

Financials of Aarey Drugs

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital17171718232323232525282828
Reserves18192031576369758892105110120
Borrowings +611151031618181438313551
Other Liabilities +6769748386438411611713613911794
Total Liabilities107115125142170146194233245291303291294
Fixed Assets +46812121212141414131625
CWIP0000000000000
Investments0000000000122
Other Assets +102109117130157133181218230277289272267
Total Assets107115125142170146194233245291303291294

Financials of Aarey Drugs

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +-0361-201350-1-310
Cash from Investing Activity +2-2-3-5-1-1-1-3-30-2-6
Cash from Financing Activity +-1-2-2423-2-2-2216-4
Net Cash Flow0-11-12-300-011-0
Free Cash Flow-113-4-21-123-2-2-45
CFO/OP-32%239%560%28%-232%37%135%154%36%13%-37%421%

Financials of Aarey Drugs

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days11911410875100109118170101165170103
Inventory Days107351623212011263336
Days Payable119117108718440981208611512381
Cash Conversion Cycle95393292426926768058
Working Capital Days5249403469779991688910689
ROCE %6%7%7%22%14%12%8%9%10%6%6%6%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals